Furthermore, TLSs can predict the responses to anti-PD‐1 immunotherapy and might be a target of PD‐1 blockade in several tumors including esophageal carcinoma, bladder cancer, melanoma and head and neck squamous cell carcinoma (HNSCC) (7–9, 11). Here, PDCD1 is linked to carcinoma of esophagus.